Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.

To elucidate interpatient variability in thioguanine nucleotide (TGN) concentrations in acute lymphoblastic leukemia (ALL) cells, we determined the TGN concentrations in leukemic blasts from 82 children with newly diagnosed ALL after intravenous administration of mercaptopurine (MP). Patients treated with MP alone achieved higher TGN concentrations than those treated with the combination of methotrexate plus mercaptopurine (MTX + MP). Analysis of the expression of approximately 9600 genes in ALL cells obtained at diagnosis identified 60 gene probes significantly associated with TGN accumulation in patients treated with MP alone and 75 gene probes in patients treated with MTX + MP, with no overlap between the 2 sets of genes. Genes significantly associated with intracellular TGN accumulation after MP alone included those encoding MP metabolic enzymes and transporters (eg, SLC29A1). Inhibition of SLC29A1 by nitrobenzylmercaptopurine ribonucleoside (NBMPR) caused a 33% to 45% reduction of TGN in ALL cells in vitro (P < .006), consistent with the gene expression findings. Genes associated with TGN concentration after combination therapy included those involved in protein and adenosine triphosphate (ATP)-biosynthesis. Together, these in vivo and in vitro data provide new insight into the genomic basis of interpatient differences in intracellular TGN accumulation and reveal significant differences between treatment with MP alone and treatment with MP and MTX.

[1]  S. Antonarakis,et al.  Cloning of the cDNA for the human ATP synthase OSCP subunit (ATP5O) by exon trapping and mapping to chromosome 21q22.1-q22.2. , 1995, Genomics.

[2]  S. Yao,et al.  Cloning of a human nucleoside transporter implicated in the Cellular uptake of adenosine and chemotherapeutic drugs , 1997, Nature Medicine.

[3]  J. A. Nelson,et al.  Characterization of the DNA damage in 6-thioguanine-treated cells. , 1990, Biochemical pharmacology.

[4]  L. Page.  Basic biochemical effects and mechanism of action of 6-thioguanine. , 1963 .

[5]  G. Lyon,et al.  Identification of 6-methylmercaptopurine ribonucleoside 5'-diphosphate and 5'-triphosphate as metabolites of 6-mercaptopurine in man. , 1974, Cancer research.

[6]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[7]  W. Evans,et al.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.

[8]  S. Purcell,et al.  Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin. , 1984, The Journal of biological chemistry.

[9]  Joanne Wang,et al.  (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters , 2004 .

[10]  J. Nakamura,et al.  Biochemical Characterization of Human GMP Synthetase (*) , 1995, The Journal of Biological Chemistry.

[11]  R. Stern,et al.  Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. , 1976, The Journal of clinical investigation.

[12]  M. Masquelier,et al.  On the paradoxically concentration-dependent metabolism of 6-mercaptopurine in WEHI-3b murine leukemia cells. , 1990, Cancer research.

[13]  R. D. De Abreu,et al.  Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. , 1988, Biochemical pharmacology.

[14]  J. Lilleyman,et al.  Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. , 1993, British journal of clinical pharmacology.

[15]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Relling,et al.  HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. , 2002, Clinical chemistry.

[17]  William C Reinhold,et al.  Membrane Transporters and Channels , 2004, Cancer Research.

[18]  R. Meyn,et al.  6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. , 1984, Cancer research.

[19]  M. Relling,et al.  De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. , 2002, Blood.

[20]  M. Relling,et al.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999, Blood.

[21]  L. Slørdal,et al.  Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. , 1995, Cancer research.

[22]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[23]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[24]  W. Evans,et al.  Pharmacogenetics of cancer therapy: getting personal. , 1998, American journal of human genetics.

[25]  M. Relling,et al.  Thioguanine substitution alters DNA cleavage mediated by topoisomerase II , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  B. Bostrom,et al.  Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. , 1993, The American journal of pediatric hematology/oncology.

[27]  M. Relling,et al.  Moving towards individualized medicine with pharmacogenomics , 2004, Nature.

[28]  C. Galmarini,et al.  In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia , 2002, British journal of haematology.

[29]  E. Jabs,et al.  Chromosomal localization of genes required for the terminal steps of oxidative metabolism: α and γ subunits of ATP synthase and the phosphate carrier , 1994, Human Genetics.

[30]  Karen Engel,et al.  Mammalian nucleoside transporters. , 2004, Current drug metabolism.

[31]  J. Lilleyman,et al.  Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia , 1994, The Lancet.

[32]  M. Relling,et al.  Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Ching-Hon Pui,et al.  Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.

[34]  R. Riccardi,et al.  Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? , 1983, The New England journal of medicine.

[35]  J. Bökkerink,et al.  Determination of extracellular and intracellular thiopurines and methylthiopurines with HPLC , 1995 .

[36]  M. Relling,et al.  Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up‐front treatment of acute lymphoblastic leukemia , 2003, Clinical pharmacology and therapeutics.

[37]  R. D. De Abreu,et al.  6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. , 1993, Biochemical pharmacology.

[38]  J. Lilleyman,et al.  Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[40]  R. Weinshilboum,et al.  Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations , 1987, Clinical pharmacology and therapeutics.

[41]  J. Downing,et al.  Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.

[42]  M. Relling,et al.  A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  T. Shimizu,et al.  Biochemical basis of the prevention of 6-thiopurine toxicity by the nucleobases, hypoxanthine and adenine. , 1990, Leukemia research.

[44]  G. Elion.  The Purine Path to Chemotherapy , 1989 .

[45]  C. Pui,et al.  Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. , 1996, Leukemia.

[46]  W. Evans,et al.  Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. , 1995, Molecular pharmacology.

[47]  W. Evans,et al.  Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. , 1999, Molecular pharmacology.

[48]  R. Murphy,et al.  The effect of methotrexate on the bioavailability of oral 6‐mercaptopurine , 1987, Clinical pharmacology and therapeutics.

[49]  Dmitri V Zaykin,et al.  Multiple tests for genetic effects in association studies. , 2002, Methods in molecular biology.

[50]  M. Relling,et al.  Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies , 1997, Leukemia.

[51]  M. Relling,et al.  Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. , 2001, Cancer research.

[52]  C. Pui,et al.  Acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[53]  B. Chabner,et al.  Inhibition of first‐pass metabolism in cancer chemotherapy: Interaction of 6‐mercaptopurine and allopurinol , 1983, Clinical pharmacology and therapeutics.

[54]  J. Lilleyman,et al.  Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. , 1996, Therapeutic drug monitoring.

[55]  M. Relling,et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Y. Ling,et al.  Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. , 1992, Molecular pharmacology.

[57]  L. Mangravite,et al.  Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. , 2003, European journal of pharmacology.

[58]  S. Hunger,et al.  Childhood leukemia--new advances and challenges. , 2004, The New England journal of medicine.

[59]  A. Bleyer,et al.  Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. , 1998, Blood.

[60]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[61]  W. Bodell.  Molecular dosimetry of sister chromatid exchange induction in 9L cells treated with 6-thioguanine. , 1991, Mutagenesis.

[62]  E. Jabs,et al.  Chromosomal localization of genes required for the terminal steps of oxidative metabolism: alpha and gamma subunits of ATP synthase and the phosphate carrier. , 1994, Human genetics.